After a two-day public meeting on July 23rd and 24th, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to recommend six peptides be added to Section 503A Bulk Drug Substances List. The six recommended peptides include BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax.
What This Likely Means Going Forward
The PCAC’s vote is only advisory, not binding. The FDA must still weigh their recommendation, issue a proposed rule, run a notice and comment period, and publish a final rule. But a 6-of-7 favorable vote is a strong signal, and it makes it likely that FDA ultimately adds most or all of these six peptides to the 503A Bulks List.
Why the Bulks List Matters
The 503A Bulks List determines which bulk drug substances a licensed compounding pharmacy may legally use to prepare an individualized, patient-specific medication when no FDA-approved finished product or applicable United States Pharmacopeia/National Formulary monograph already covers that substance. Without a substance’s inclusion on this list (or another statutory pathway), a 503A compounding pharmacy generally cannot compound it.
Current Sales and New 503A Prescription Model
Currently, physicians are not permitted to prescribe, and pharmacies not permitted to prepare, medications containing these peptides. Nor can these peptides be sold as a ‘dietary supplement.’
Attempting to avoid regulatory scrutiny, many vendors sell peptides online with disclaimers like “research purposes only” and “not for human consumption.” But this approach is highly risky and has led to numerous enforcement actions.
If the FDA follows the PCAC’s recommendation, it will create a new, safe pathway to dispense peptides. If a peptide is added to the list, physicians and, where permitted under state law, APRNs and PAs, will be able to write prescriptions for that peptide to a licensed 503A compounding pharmacy for any purpose, pursuant to a valid patient specific prescription.
The Telehealth Opportunity
Assuming a peptide is added to the list, the practical result is a telehealth prescribing model where a licensed prescriber conducts a qualifying evaluation via telehealth and routes the prescription to a 503A compounding pharmacy for fulfillment.
Our healthcare team is closely tracking this rulemaking and regularly advises prescribers, pharmacies, and telehealth platforms on building compliant peptide prescribing programs. If you’re evaluating entering this space, we’d welcome the opportunity to talk through how you might be able to implement prescription or dispensing of certain peptides into your business model.
This article is provided for general informational purposes only and does not constitute legal advice. Reading or relying on this content does not create an attorney–client relationship. For advice regarding your specific situation, consult with a qualified healthcare attorney at Nichols Weitzner Thomas LLP.
